The Dangerous Over-Prescribing of Psychiatric Medications in Children
The number of children in the United States receiving psychiatric medications has risen dramatically over the past three decades.
Stimulant prescriptions for ADHD have increased substantially and show no signs of reversing. Antidepressants and anti-anxiety medications are prescribed to children at growing rates, including to very young children. Antipsychotic medications — originally developed for adults with severe psychiatric illness — are now routinely used in children, often off-label, for conditions ranging from irritability to sleep difficulties.
These trends should prompt serious questions. Not because psychiatric medication is never appropriate for children — in some cases, it clearly is. But because medication at scale, as a first-line response to childhood behavioral and emotional difficulties, carries risks that deserve careful attention. And because, for many of these children, there are identifiable biological factors that could be addressed without — or before — reaching for a prescription.
The Scale of the Problem
Current estimates suggest that over 10% of school-age children in the United States are taking some form of psychiatric medication at any given time. The rates are particularly high for boys, particularly in school contexts, and disproportionately affect certain socioeconomic and racial groups.
This is not primarily the result of better diagnosis. It is the result of a structural tendency to apply pharmacological solutions to behavioral presentations without adequate investigation of underlying causes.
A child who is inattentive, impulsive, anxious, or emotionally dysregulated is presenting with real difficulties that deserve real attention. The question is whether the right first response is medication — or whether it should be a genuine investigation of why this particular child’s brain and nervous system are struggling.
The Developing Brain Is Different
The most important thing to understand about psychiatric medication in children is that a child’s brain is not a small adult brain. It is a rapidly developing organ at a critical stage of construction.
The prefrontal cortex — responsible for executive function, impulse control, and emotional regulation — continues developing into the mid-20s. The neurotransmitter systems that psychiatric medications target are in flux throughout childhood and adolescence, not yet settled into the patterns they will eventually stabilize around.
What this means, practically, is that we don’t fully understand the long-term consequences of exposing a developing brain to drugs that alter neurotransmitter activity during sensitive periods of development. The research on long-term outcomes is limited because these prescribing trends are relatively recent — we don’t yet have the longitudinal data.
What we do have is mechanistic reason for caution. The dopaminergic system is heavily implicated in motivational development, reward processing, and the formation of goal-directed behavior. Stimulants — the most prescribed class of psychiatric drugs in children — directly modulate this system. Using stimulants during the developmental period when these systems are forming is not a risk-neutral decision.
The Side Effect Profile Is Not Trivial
Current psychiatric medications used in children carry real side effect burdens:
Stimulants (Adderall, Ritalin, Vyvanse):
- Growth suppression — multiple studies have found that stimulant use in childhood is associated with reduced height velocity, with cumulative effects that may persist
- Cardiovascular effects — increased heart rate and blood pressure
- Appetite suppression leading to nutritional deficits (nutritional deficits that, ironically, can worsen the very symptoms the medication is treating)
- Sleep disruption — stimulants frequently worsen sleep quality, creating or worsening a secondary problem
- Emotional blunting — some children on stimulants describe feeling “flat” or less themselves
- Rebound irritability when doses wear off
Antidepressants in children:
- The FDA placed a black box warning on SSRIs for children and adolescents in 2004, noting increased risk of suicidal ideation in this population
- Activation symptoms — anxiety, agitation, insomnia — particularly in the early weeks of treatment
- Growth and developmental effects that are not fully characterized
Atypical antipsychotics (Risperdal, Abilify, Seroquel):
- Metabolic effects — significant weight gain, insulin resistance, elevated blood sugar
- Tardive dyskinesia risk (involuntary movement disorder) with long-term use
- Prolactin elevation and associated endocrine effects
- Sedation affecting learning and cognitive function
- These drugs are among the most powerful available to psychiatry, and their use in children for irritability, sleep, or behavioral symptoms represents a significant risk-benefit calculation that is often not made with sufficient care
The Question That Often Goes Unasked
When a child presents with ADHD, anxiety, mood instability, or behavioral difficulties, the clinical question that drives most conventional treatment is: Which medication is indicated for this presentation?
The question that should also be asked — and in most clinical settings, isn’t — is: Why is this child’s brain functioning this way, and is there a correctable biological cause?
The answer to that question, when properly investigated, often reveals:
- Zinc deficiency: Affecting dopamine synthesis and GABA function — directly contributing to attention, impulsivity, and anxiety
- Iron deficiency: (ferritin below optimal range) affecting dopamine production and concentration
- Pyrrole disorder: Driving chronic zinc and B6 depletion, producing anxiety, emotional dysregulation, and attentional difficulties
- Copper toxicity: Contributing to hyperactivity, sensory sensitivity, and emotional volatility
- Gut dysbiosis: Producing neuroinflammation that affects behavior and cognition
- Magnesium deficiency: Affecting NMDA receptor regulation and hyperexcitability
- Food sensitivities or intolerances: Producing systemic inflammation and behavioral symptoms
- Heavy metal exposure: Affecting neurological function
Each of these has a specific, targeted, non-pharmacological intervention. And each of them is being missed when the clinical response to a child’s behavioral difficulties begins and ends with a prescription.
The Nutrient-Medication Interaction Problem
There is an additional layer of concern that is almost never discussed: many psychiatric medications deplete the very nutrients that are needed to support brain function and, in some cases, that are contributing to the presenting symptoms.
- Stimulants are appetite suppressants, often significantly reducing the intake of zinc, iron, and other nutrients that affect dopamine and attention
- Valproate (Depakote) depletes carnitine, zinc, and B vitamins
- SSRIs have documented effects on zinc metabolism
- Atypical antipsychotics affect folate and B12 absorption
A child who starts a stimulant for ADHD may have their zinc intake further reduced by medication-induced appetite suppression — worsening the very zinc deficiency that was contributing to their attention difficulties in the first place. This creates a cycle in which medication seems to be working partially, but the underlying nutritional issue continues to worsen.
What a More Complete Standard of Care Would Look Like
This is not an argument that all psychiatric medication for children should be eliminated. Some children are severely impaired and need medication to function safely. Some conditions have better evidence for pharmacological treatment than for purely nutritional approaches. Some parents and children, after being fully informed, choose medication as part of their management plan and that is their right.
But a more complete standard of care would, at minimum:
- Assess nutritional status before initiating medication — particularly zinc, ferritin, magnesium, and vitamin D, along with pyrrole disorder and copper-zinc balance
- Address identified deficiencies before defaulting to medication, or at minimum alongside medication
- Assess gut health in children with behavioral difficulties, given the strong gut-brain connection
- Provide informed consent about medication side effects and the limitations of current long-term safety data
- Revisit medication need regularly as biochemistry is addressed and the brain matures
This is a higher standard than what most children currently receive. But it’s the standard they deserve.
Your child deserves a more complete evaluation before medication is considered the answer.
At MN Mensah Medical, we specialize in identifying the biochemical factors that contribute to children’s behavioral, emotional, and attentional difficulties. Our comprehensive evaluation often reveals treatable biological causes that conventional assessment misses.
Schedule a consultation to get the full picture before making long-term decisions about your child’s care.